NEW YORK, Nov. 11, 2014 /PRNewswire/ -- Vesselon, Inc. today announced the appointment of Paul S. Auerbach, MD to its Scientific Advisory Board, effective immediately. Dr. Auerbach's selection comes during Vesselon's engagement with Spencer Trask Ventures, Inc. as its placement agent to market a private preferred Series A round to develop and commercialize Vesselon's immediate and early stroke treatment, as well as potentially other noninvasive vascular therapeutics.
"Dr. Auerbach has an exceptionally broad background in both emergency medicine and early stage medical ventures and will provide invaluable expertise to Vesselon as we seek to bring to market a new clinical domain of early and immediate noninvasive vascular therapeutics using ultrasound and microbubbles," stated Clay Larsen, President, CEO and Co-Founder of Vesselon. "We are fortunate to have him contribute to our initial developments of an immediate stroke treatment that can be compared to an automated external defibrillator (AED) for stroke."
Paul S. Auerbach, MD, MS, FACEP, FAWM is the Redlich Family Professor of Surgery and Acting Chief of the Division of Emergency Medicine at Stanford University School of Medicine. From 2003 to 2004, Dr. Auerbach served as the Chief Operating Officer of KAI Pharmaceuticals, Inc., a developmental and discovery pharmaceutical company. From 1999 through 2003 he was a partner at Delphi Ventures, a venture capital firm that specializes in early-stage healthcare investing. From 1997 to 1999, Dr. Auerbach was the Chief Operating Officer of MedAmerica, a medical practice support and consulting company. Dr. Auerbach is a founder and past president of the Wilderness Medical Society, editor of the definitive medical reference text Wilderness Medicine and author of Medicine for the Outdoors, which is the leading book on outdoor health for laypersons. Dr. Auerbach practices emergency medicine, teaches, performs research, and advises numerous agencies and organizations, including serving as a volunteer physician in Haiti, Nepal, and Guatemala. He is an elected member of the Council on Foreign Relations. Dr. Auerbach has been hailed as a Hero of Emergency Medicine by the American College of Emergency Physicians. He also serves on the National Medical Committee for the National Ski Patrol. Dr. Auerbach is a recipient of numerous awards, including the DAN America Award from the Divers Alert Network, Outstanding Contribution in Education Award from the American College of Emergency Physicians, a NOGI Award in 2006 from the Academy of Underwater Arts and Sciences, Diver of the Year for Science in 2008 from Beneath the Sea, and DAN/Rolex Diver of the Year in 2009. Dr. Auerbach is a graduate of Duke University and Duke University School of Medicine, as well as the Stanford Graduate School of Business.
"In emergency medicine, there are few events as significant and widespread as stroke, yet there are a paucity of interventions with which to treat this devastating and costly condition at an early stage after onset. Having an effective and safe pre-hospital treatment would be huge," stated Dr. Auerbach, "so I'm very interested in helping Vesselon determine and demonstrate their treatment's effectiveness."
Vesselon is a development stage company that is creating one of the world's first battery powered mobile devices for the immediate treatment of ischemic stroke -- the most common type of stroke affecting 87% of patients. Vesselon's product is an ultrasound device that is intended to be used by paramedics in the field, professionals trained in advanced life support skills, and physicians in hospitals to treat stroke victims early. The portable, noninvasive device is being developed to use non-imaging ultrasound, along with intravenous-administered microbubbles, to dissolve clots in the cerebrovascular or cardiovascular system.
Vesselon, Inc., a Spencer Trask venture, is a development stage medical device company seeking to transform ischemic stroke treatment. We are developing a new immediate treatment platform that will use non-imaging ultrasound and a contrast agent of microbubbles to dissolve clots. Just as the introduction of the AED enabled first responders to save cardiac arrest victims' lives, we believe our device could reduce treatment time from hours to minutes and have the potential to save the lives of and quality of life for ischemic stroke victims.
About Spencer Trask Ventures
For more than 20 years, Spencer Trask Ventures, Inc. has united investors and entrepreneurs to build valuable companies that better the world. Our clients have invested more than $1 billion in start-up companies that went on to make significant advances in healthcare, technology and life sciences.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. This press release may contain certain statements of a forward-looking nature relating to future events or future business performance. Any such statements that refer to the Company's estimated or anticipated future results or other non-historical facts are forward-looking and reflect the Company's current perspective of existing trends and information. These statements involve risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. The forward-looking statements speak only as of the date of this release. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Vesselon, Inc.